Sort
53,477 grants matching “addiction”
Neurobiology of Addiction
$2,823,151George Koob · National Institute On Drug Abuse · ZIA · FY2024 · DA
Associative learning, decision-making, and addiction
$2,823,042Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2012 · DA
Investigation On The Behavioral Effects And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.
$2,820,374Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2024 · DA
WormBase: a core data resource for C elegans and other nematodes
$2,818,076Paul Warren Sternberg · California Institute Of Technology · P41 · FY2011 · HG
Neurobiology of Addiction
$2,816,061George Koob · National Institute On Drug Abuse · ZIA · FY2025 · DA
WormBase: a core data resource for C elegans and other nematodes
$2,815,263Paul Warren Sternberg · California Institute Of Technology · P41 · FY2012 · HG
Microdialysis Studies of Self-administrationx
$2,810,493Roy A Wise · National Institute On Drug Abuse · ZIA · FY2010 · DA
Targeting GPCRs in amygdalar and cortical neural ensembles to treat pain aversion
$2,802,899Gregory Scherrer · Univ Of North Carolina Chapel Hill · R01 · FY2020 · NS
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
$2,800,991Valerie Odero-Marah · Morgan State University · U54 · FY2021 · MD
Randomized ESRD Trial COmparing CBT alone VERsus with buprenorphine (RECOVER)
$2,800,151Rajnish Mehrotra · University Of Washington · U01 · FY2019 · DK
Illuminating neural coding mechanisms using in vivo calcium imaging in freely behaving rodents
$2,799,458Da-Ting Lin · National Institute On Drug Abuse · ZIA · FY2023 · DA
Appalachian Node
$2,799,142Jane M Liebschutz · University Of Pittsburgh At Pittsburgh · UG1 · FY2019 · DA
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.
$2,798,940Hugh William Alsop · Kinoxis Therapeutics Pty Ltd · UG3 · FY2019 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial
$2,794,315Lynn Kirkpatrick · Ensysce Biosciences, Inc. · UH3 · FY2022 · DA
NOP Receptor Antagonist for OUD Pharmacotherapy
$2,793,808Kathryn A. Cunningham · University Of Texas Med Br Galveston · UG3 · FY2020 · DA
Alcohol Pharmacokinetics and Pharmacodynamics in Humans
$2,793,277Vijay Arjun Ramchandani · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2020 · AA
Mouse models of stress disorders and addiction
$2,792,466Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial
$2,791,255Lynn Kirkpatrick · Ensysce Biosciences, Inc. · UH3 · FY2021 · DA
Hub and Spoke Opioid Treatment Networks: 2nd Generation Approaches to Improve Medication Treatment for Opioid Use Disorders
$2,785,111Sharon Reif · Brandeis University · R01 · FY2019 · DA
Project-003
$2,784,993Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2023 · DA
Methodology and Advanced Analytics Resource Center 2.0
$2,783,616John Schneider · University Of Chicago · UM1 · FY2025 · DA
Selective actin remodeling of sensory neurons for acute pain management
$2,776,138Paul Blum · Neurocarrus, Inc. · R44 · FY2023 · NS
\SINGLE ASCENDING DOSE (SAD) PHASE I STUDY
$2,773,098Craig Boyle · Ppd Development Lp · N01 · FY2024 · DA
Injectable naltrexone 2-month depot formulations
$2,768,235Kinam Park · Purdue University · UH3 · FY2024 · DA
Substance Abuse Medications Development Research Center
$2,766,981Frederick Gerard Moeller · University Of Texas Hlth Sci Ctr Houston · P50 · FY2009 · DA